A novel <scp><i>GAB2::BRAF</i></scp> fusion in cutaneous non‐Langerhans‐cell histiocytosis with systemic involvement
Bicong Wu(Tongji Hospital), Ata S. Moshiri(New York University), Paul C. Hendrie(University of Washington), Erik L. Kimble(University of Washington), Michi M. Shinohara(University of Washington), Eric Q. Konnick(Brotman Baty Institute)
Cited by 3
Related Papers
Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era
|Blood|2020|397
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies
|Blood|2020|217
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|172
Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy
|Transplantation and Cellular Therapy|2023|144